Johnson & Johnson's subcutaneous injection dual therapy approved for marketing in China, reducing administration time to approximately 5 minutes.

On December 25th, Johnson & Johnson (JNJ.US) announced that its innovative treatment drug, AVEKTEN (Evans Single Domain Antibody Injection) officially received approval from the Chinese NMPA for the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. The subcutaneous injection formulation of AVEKTEN provides patients with greater convenience, reducing the administration time from several hours to approximately 5 minutes, while also reducing the incidence of infusion-related adverse reactions by 80% compared to intravenous injection formulations. AVEKTEN is a fully human EGFRMET bispecific antibody. The subcutaneous injection formulation of AVEKTEN contains recombinant human hyaluronidase (rHuPH20) and utilizes Halozyme's ENHANZE drug delivery technology, allowing for administration in just about 5 minutes. This innovation not only has the potential to improve patients' quality of life by giving them more time to return to normal life, but also helps optimize medical resource allocation and promote the sustainable development of the Chinese healthcare system. Cherry Huang, President of Innovative Pharmaceuticals at Johnson & Johnson China, stated that around 40% of lung cancer patients in China carry EGFR mutations. This approval is a milestone, further solidifying the important role of AVEKTEN in the treatment of EGFR mutated NSCLC. This patient population has significant unmet medical needs, and the subcutaneous injection formulation of AVEKTEN offers a more convenient dosing option with better tolerability for patients and clinical doctors, while maintaining good efficacy and controllable safety.